Patent Issued for Antibodies against claudin 18.2 useful in cancer diagnosis (USPTO 11976130).
In: Women's Health Weekly, 2024-05-28, S. 1351-1351
serialPeriodical
Zugriff:
Astellas Pharma Inc. has been issued a patent for antibodies against claudin 18.2, which are useful in cancer diagnosis. The patent describes the structure and function of claudin 18.2, a transmembrane protein found in tight junctions of epithelial and endothelial cells. The invention relates to antibodies that bind to claudin 18.2 and can be used for cancer treatment and detection. The patent also includes methods for treating cancer, detecting claudin 18.2 expression, and diagnosing cancer using these antibodies. This information may be useful for researchers and healthcare professionals working in the field of oncology. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Antibodies against claudin 18.2 useful in cancer diagnosis (USPTO 11976130).
|
---|---|
Zeitschrift: | Women's Health Weekly, 2024-05-28, S. 1351-1351 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Schlagwort: |
|
Sonstiges: |
|